Therapies targeting signaling pathways such as the CDK4/6 and the PI3K/AKT/mTOR pathway that have been identified among the pathways involved in endocrine therapy resistance (Johnston, 2015) have provided a significant clinical benefit in ER+ BC. Here, AKT1 is linked to breast cancer.